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individual enantiomers were calculated with reference to the IC50 
values shown in table 3.6.  The graph obtained was from the third 
antibody bleed. 
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Figure 3.5(ii) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit A towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.6.  The graph obtained was from the seventh 
antibody bleed. 
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Figure 3.5(iii) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit A towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.6.  The graph obtained was from the tenth 
antibody bleed. 
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Figure 3.5(iv) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit A towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.6.  The graph obtained was from the twelfth 
antibody bleed. 
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Figure 3.6(i) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit S towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.7.  The graph obtained was from the second 
antibody bleed. 
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Figure 3.6(ii) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit S towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.7.  The graph obtained was from the fourth 
antibody bleed. 
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Figure 3.6(iii) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit S towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.7.  The graph obtained was from the sixth 
antibody bleed. 
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Figure 3.6(iv) The concentration response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit S towards salbutamol racemate and the 
individual enantiomers were calculated with reference to the IC50 
values shown in table 3.7.  The graph obtained was from the eighth 
antibody bleed. 
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Figure 3.7 The molecular structure of salbutamol with the stereogenic centre 
marked with *. 
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Figure 3.8(i) The figure above showed the MALDI TOF/TOF linear spectra 
obtained for (R)-salbutamol (MA)-BSA depicting that the 
immunogen molecular weight was 72502.8594.  The ionization of the 
immunogen resulted in a singly and doubly charged ions. 
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Figure 3.8(ii) The figure above showed the MALDI TOF/TOF linear spectra for 
BSA only depicting that the molecular weight of the carrier protein 
was 66524.7422.  The ionization of BSA resulted in a singly and 
doubly charged ions. 
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Figure 3.9(i) The figure above showed the MALDI TOF/TOF linear spectra 
obtained for (R)-salbutamol (BDDE)-BSA depicting that the 
immunogen molecular weight was 70983.3516.  The ionization of the 
immunogen resulted in a singly and doubly charged ions. 
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Figure 3.9(ii) The figure above showed the MALDI TOF/TOF linear spectra for 
BSA only depicting that the molecular weight of the carrier protein 
was 66521.3516.  The ionization of BSA resulted in a singly and 
doubly charged ions. 
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Figure 3.10(i) The figure showed the MALDI TOF/TOF linear spectra obtained for 
(S)-salbutamol (BDDE)-BSA depicting that the immunogen 
molecular weight was 71525.1094.  The ionization of the immunogen 
resulted in a singly and doubly charged ions. 
124 
Figure 3.10(ii) The figure showed the MALDI TOF/TOF linear spectra for BSA 
only depicting that the molecular weight of the carrier protein was 
66616.0938.  The ionization of BSA resulted in a singly and doubly 
charged ions. 
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Figure 3.11(i) The concentration response curve of (R)-salbutamol (MA) polyclonal 
antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.15.  The graph obtained was from the first antibody bleed. 
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Figure 3.11(ii) The concentration response curve of (R)-salbutamol (MA) polyclonal 
antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.15.  The graph obtained was from the fourth antibody 
bleed. 
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Figure 3.11(iii) The concentration response curve of (R)-salbutamol (MA) polyclonal 
antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.15.  The graph obtained was from the sixth antibody bleed. 
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Figure 3.11(iv) The concentration response curve of (R)-salbutamol (MA) polyclonal 
antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.15.  The graph obtained was from the eighth antibody 
bleed. 
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Figure 3.12(i) The concentration response curve of (R)-salbutamol (BDDE) 
polyclonal antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.16.  The graph obtained was from the first antibody bleed. 
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Figure 3.12(ii) The concentration response curve of (R)-salbutamol (BDDE) 
polyclonal antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.16.  The graph obtained was from the third antibody bleed. 
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Figure 3.12(iii) The concentration response curve of (R)-salbutamol (BDDE) 
polyclonal antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.16.  The graph obtained was from the fourth antibody 
bleed. 
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Figure 3.12(iv) The concentration response curve of (R)-salbutamol (BDDE) 
polyclonal antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.16.  The graph obtained was from the ninth antibody bleed. 
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Figure 3.13(i) The concentration response curve of (S)-salbutamol (BDDE) 
polyclonal antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.17.  The graph obtained was from the first antibody bleed. 
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Figure 3.13(ii) The concentration response curve of (S)-salbutamol (BDDE) 
polyclonal antibody towards salbutamol racemate and the individual 
enantiomers were calculated with reference to the IC50 values shown 
in table 3.17.  The graph obtained was the second antibody bleed. 
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Figure 4.1 The chiral stationary phase of Chirex 3022 (S)-indoline-2-carboxylic 
acid and (R)-1-(alpha-napthyl)ethylamine that is of Pirkle type 
column.  [Online].  Date accessed: 18 May 2014.  Adapted from 
http://www.phenomenex.com/Products/HPLCDetail/Chirex/3022%2
0%28S%29-indoline-2-carboxylic%20acid%20and%20%28R%29-1-
%28alpha-napthyl%29ethylamine?returnURL=/Search&phase. 
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Figure 4.2 The chiral stationary phase of Astec CHIROBIOTIC™ T HPLC 
chiral column.  [Online].  Date accessed: 18 May 2014.  Adapted 
from: http://www.sigmaaldrich.com/japan/analytical-
chromatography/hplc/chiral-astec/chirobiotic.html#03. 
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Figure 4.3 Schematic diagram of a typical SPE sequence.  Adapted from: 
European Mycotoxins Awareness Network.  [Online].  Date 
accessed: 18 May 2014.  
http://services.leatherheadfood.com/eman/FactSheet.aspx?ID=61. 
149 

  Page 
Figure 4.4(i) Salbutamol product ion produced as a result of loss of two water 
molecules and the tertiary butyl group (Joyce et al., 1998).  The 
molecule also underwent a molecular structure rearrangement 
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Figure 4.4(ii) Proposed salbutamol-tert-butyl-d9 product ion formed with similar 
losses of two water molecules and the tertiary butyl group made up of 
9 deuteriums.  The molecule underwent molecular rearrangement but 
retained one of the deuteriums with the amine moiety. 
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Figure 4.5 Typical chiral MRM chromatogram of salbutamol and salbutamol-
tert-butyl-d9 separated by the Astec CHIROBIOTIC™ T column (10 
cm x 3.0 mm; 5 µm).  The (R)- enantiomers were less retained by the 
column and thus showed a shorter retention time compared with the 
(S)- enantiomer. 
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Figure 4.6 Typical chiral MRM chromatogram of blank porcine urine sample 
chromatographically separated by the Astec CHIROBIOTIC™ T 
column (10 cm x 3.0 mm; 5 µm).  There was no matrix interference 
observed for salbutamol at MRM: 240.2 → 148.1; and 240.2 → 
222.2 in the sample. 
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Figure 4.7(a) The salbutamol enantiomer calibration curves were represented by 
(R)-salbutamol ranging from 0-10 ng/mL (RS)-salbutamol.  They 
were obtained as a result of spiked porcine urine extracted using 
sequential SPE method and analysed with the Agilent Technologies 
6460 Triple Quad LC/MS.  The chiral separation was obtained using 
the Astec CHIROBIOTIC™ T column (10 cm x 3 mm, 5 µm). 
157 
Figure 4.7(b) The salbutamol enantiomer calibration curves were represented by 
(S)-salbutamol ranging from 0-10 ng/mL (RS)-salbutamol.  They 
were obtained as a result of spiked porcine urine extracted using 
sequential SPE method and analysed with the Agilent Technologies 
6460 Triple Quad LC/MS.  The chiral separation was obtained using 
the Astec CHIROBIOTIC™ T column (10 cm x 3 mm, 5 µm). 
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Figure 4.8(a) The typical salbutamol enantiomer calibration curves were 
represented by (R)-salbutamol ranging from 0-10 ng/mL (RS)-
salbutamol.  They were obtained as a result of spiked porcine urine 
extracted using sequential SPE method and analysed with the Agilent 
Technologies 6460 Triple Quad LC/MS.  The chiral separation was 
obtained using the Astec CHIROBIOTIC™ T column (10 cm x 3 
mm, 5 µm). 
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Figure 4.8(b) The typical salbutamol enantiomer calibration curves were 
represented by (S)-salbutamol ranging from 0-10 ng/mL (RS)-
salbutamol.  They were obtained as a result of spiked porcine urine 
extracted using sequential SPE method and analysed with the Agilent 
Technologies 6460 Triple Quad LC/MS.  The chiral separation was 
obtained using the Astec CHIROBIOTIC™ T column (10 cm x 3 
mm, 5 µm). 
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Figure 4.9(i) The functional group linked onto the mixed-mode SPE sorbent is a 
cation exchanger and a hydrophobic group.  [Online].  Date accessed: 
18 May 2014.  Adapted from http://www.biotage.com/product-
page/isolute-hcx. 
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Figure 4.9(ii) The functional group linked onto the mixed-mode SPE sorbent is an 
anion exchanger and a hydrophobic group.  [Online].  Date accessed: 
18 May 2014.  Adapted from http://www.biotage.com/product-
page/isolute-hax. 
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Figure 4.10 Mechanism of boronic acid extraction.  The upper scheme shows 
boronic acid activation in alkaline pH.  The middle scheme shows 
covalent bonding between boronic acid and salbutamol.  The final 
scheme shows the breaking of the covalent bond with acid and 
regenerates the boronic acid and frees the salbutamol.  Adapted from 
Wilson and Martin (2000). 
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Figure 5.1(i) Chromatogram for chiral analysis of salbutamol-tert-butyl-d9 (IS), 
extracted with Abs Elut-Nexus SPE and analysed with Agilent 
Technologies 6460 Triple Quad LC/MS coupled to Astec 
CHIROBIOTIC™ T HPLC column. 
185 
Figure 5.1(ii) Chromatogram for chiral analysis of unhydrolysed negative porcine 
urine extracted with Abs Elut-Nexus SPE and analysed with Agilent 
Technologies 6460 Triple Quad LC/MS coupled to Astec 
CHIROBIOTIC™ T HPLC column. 
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Figure 5.1(iii) Chromatogram for chiral analysis of unhydrolysed positive porcine 
urine extracted with Abs Elut-Nexus SPE and analysed with Agilent 
Technologies 6460 Triple Quad LC/MS coupled to Astec 
CHIROBIOTIC™ T HPLC column. 
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Figure 5.1(iv) Chromatogram for chiral analysis of unhydrolysed positive equine 
urine extracted with Abs Elut-Nexus SPE and analysed with Agilent 
Technologies 6460 Triple Quad LC/MS coupled to Astec 
CHIROBIOTIC™ T HPLC column. 
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Figure 5.1(v) Chromatogram for chiral analysis of unhydrolysed positive human 
urine extracted with Abs Elut-Nexus SPE and analysed with Agilent 
Technologies 6460 Triple Quad LC/MS coupled to Astec 
CHIROBIOTIC™ T HPLC column. 
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Figure 5.2(i) Chromatogram of achiral analysis of salbutamol-tert-butyl-d9 (IS) in 
porcine urine.  It is extracted with Abs Elut-Nexus SPE and analysed 
with Agilent Technologies 6460 Triple Quad LC/MS coupled to 
LiChroCART® Purospher® STAR RP-18 endcapped HPLC column. 
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Figure 5.2(ii) Chromatogram of achiral analysis of salbutamol-3-O-glucuronide in 
equine urine.  It is extracted with Abs Elut-Nexus SPE and analysed 
with Agilent Technologies 6460 Triple Quad LC/MS coupled to 
LiChroCART® Purospher® STAR RP-18 endcapped HPLC column. 
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Figure 5.2(iii) Chromatogram of achiral analysis showing the absence of 
salbutamol-3-O-glucuronide in porcine urine.  It is extracted with 
Abs Elut-Nexus SPE and analysed with Agilent Technologies 6460 
Triple Quad LC/MS coupled to LiChroCART® Purospher® STAR 
RP-18 endcapped HPLC column. 
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Figure 5.2(iv) Chromatogram of achiral analysis of salbutamol-4-O-sulphate in 
human urine.  It is extracted with Abs Elut-Nexus SPE and analysed 
with Agilent Technologies 6460 Triple Quad LC/MS coupled to 
LiChroCART® Purospher® STAR RP-18 endcapped HPLC column. 
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Figure 5.2(v) Chromatogram of achiral analysis showing the absence of 
salbutamol-4-O-sulphate in porcine urine.  It is extracted with Abs 
Elut-Nexus SPE and analysed with Agilent Technologies 6460 Triple 
Quad LC/MS coupled to LiChroCART® Purospher® STAR RP-18 
endcapped HPLC column. 
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Figure 5.3(i) The salbutamol enantiomer calibration curve was represented by (R)-
salbutamol ranging from 0-10 ng/mL (RS)-salbutamol.  It was used 
for quantification of the salbutamol-3-O-glucuronide fraction 
collected off the LiChroCART® Purospher® STAR RP-18 
endcapped HPLC column. 
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Figure 5.3(ii) The salbutamol enantiomer calibration curve was represented by (S)-
salbutamol ranging from 0-10 ng/mL (RS)-salbutamol.  It was used 
for quantification of the salbutamol-3-O-glucuronide fraction 
collected off the LiChroCART® Purospher® STAR RP-18 
endcapped HPLC column. 
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Figure 5.4 Full scan achiral chromatogram of the purified salbutamol-4-O-
sulphate metabolite using Agilent Technologies 6460 Triple Quad 
LC/MS for purity determination.  The AUC of the metabolite at 
6.472 minutes is 2,649,233 and impurity at 3.433 minutes is 56,234. 
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Figure 5.5 The concentration-response curve of (RS)-salbutamol (MA) 
polyclonal antibody of rabbit S9 towards salbutamol racemate, 
salbutamol-tert-butyl-d9 (Internal standard, IS), and salbutamol-3-O-
glucuronide were calculated with reference to the IC50 values shown 
in table 5.9.   
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Figure 5.6 The concentration-response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit A towards salbutamol racemate, 
salbutamol-tert-butyl-d9 (Internal standard, IS), and salbutamol-3-O-
glucuronide were calculated with reference to the IC50 values shown 
in table 5.10. 
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Figure 5.7 The concentration-response curve of (RS)-salbutamol (MA) 
polyclonal antibody of rabbit S9 towards salbutamol racemate and 
salbutamol-4-O-sulphate were calculated with reference to the IC50 
values shown in table 5.11. 
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Figure 5.8 The concentration-response curve of (RS)-salbutamol (BDDE) 
polyclonal antibody of rabbit A towards salbutamol racemate and 
salbutamol-4-O-sulphate were calculated with reference to the IC50 
values shown in table 5.12. 
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LIST OF ABBREVIATIONS& SYMBOLS 
Å Angstrom 
ADME Absorption, distribution, metabolism, and excretion 
AGP α1-Glycoprotein 
AP Alkaline phosphatase 
ATP Adenosine-5’-triphosphate 
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BDDE Butane-1,4-diol diglycidyl ether 
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HPLC High performance liquid chromatography 
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HRP Horseradish peroxidase 
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KCl Potassium chloride 
kDa Kilo Dalton 
KH2PO4 Potassium di-hydrogen phosphate 
KLH Keyhole limpet haemocyanin 
KOH Potassium hydroxide 
L Litre 
LC Liquid chromatography 
LC-MS Liquid chromatography mass spectrometer 
LOD Limit of detection 
LOQ Limit of quantification 
MA Mixed anhydride 
MALDI Matrix assisted laser desorption ionization 
MDI Metered dose inhaler 
mg Milligram 
mL Millilitre 
mmole Millimoles 
Na2CO3 Sodium carbonate 
Na2HPO4 Di-sodium hydrogen phosphate 
NaCl Sodium chloride 
NaHCO3 Sodium hydrogen carbonate / sodium bicarbonate 
NaOH Sodium hydroxide 
ng Nanogram 
(NH4)2SO4 Ammonium sulphate 
OD Optical density 
OVA Ovalbumin 
PAPS 3’-phosphoadenosine-5’-phosphosulphate 
PBA Phenylboronic acid 
PEG Polyethylene glycol 
PST Phenolsulphotransferase 
RIA Radioimmunoassay 
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RT Room temperature 
SD Standard deviation 
SPE Solid-phase extraction 
SULT Sulphotransferase 
TEA Triethylamine 
TG Thyroglobulin 
TMB 3,3’,5,5’-tetramethylbenzidine  
TMCS Trimethylchlorosilane 
TOF Time of flight 
UDP Uridine-5’-diphospho- 
UHQ Ultrapure water 
WADA World Anti-Doping Agency 
β Beta 
µg Microgram 
µL Microlitre 
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GLOSSARY OF TERMINOLOGIES FOR CHIRALITY 
Achiral A molecule that is superimposable on its mirror image and has at 
least one plane of symmetry. 
Antipode Synonym of enantiomer. 
Asymmetric carbon 
atom 
A carbon atom that has four different atoms/groups/ligands 
attached. 
Chiral Having the property of chirality.  A chiral molecule is a molecule 
that is not superimposable on its mirror image.  It has no plane of 
symmetry. 
Chiral centre A tetrahedral atom in a molecule bearing four different ligands.  
Lone pair of electrons is treated as ligands.  If a chiral centre is a 
carbon atom, it can also be called an asymmetric carbon.  
Synonym: chiral atom, chirality centre, and centre of chirality. 
Chirality A fundamental property of three-dimensional objects. 
Constitutional isomers Compounds with the same molecular formula but different 
structural formulas.  Synonym: Structural isomers 
Diastereomers Stereoisomers that are not mirror images of each other.  Cis- and 
trans- isomers are a subset of diastereomers.  All cis- and trans- 
isomers are diastereomers but not all diastereomers are of the cis- 
and trans- orientation. 
Enantiomer One of a pair of molecule entities that are related to each other by 
a reflection.  They are mirror images of each other and non-
superimposable. 
Enantiomeric ratio The ratio of the percentage of one enantiomer in a mixture to that 
of the other, e.g. 70(+):30(-). 
Eudismic ratio The difference in pharmacologic activity between two 
enantiomers of a drug. 
Optical activity A sample of material able to rotate the plane of polarisation of a 
beam of transmitted plane-polarised light is said to possess optical 
activity (or to be optically active).  This optical rotation is the 
classical distinguishing characteristic (sufficient but not 
necessary) of systems containing unequal amounts of 
corresponding enantiomers.  An enantiomer causing rotation in a 
clockwise direction (when viewed in the direction facing the 
oncoming light beam) under specified conditions is called 
dextrorotatory and its chemical name or formula is designated by 
the prefix (+)-; one causing rotation in the opposite sense is 
laevorotatory and designated by the prefix (-)-.  Materials with 
optical activity also exhibit other chiroptic phenomena. 
Racemic/racemate An equimolar mixture of a pair of enantiomers.  It does not 
exhibit optical activity.  The chemical name or formula of a 
racemate is distinguished from those of the enantiomers by the 
prefix (-)- or (+)- or rac- (racem-) or by the symbols RS and SR. 

Stereochemistry A subdiscipline of chemistry involving the study of the relative 
spatial arrangement of atoms that form the structure of molecules 
and their manipulation.  An important branch of stereochemistry 
is the study of chiral molecules.  Stereochemistry is also known 
as 3D chemistry because the prefix ‘stereo’ means ‘three-
dimensionality’. 
Stereoisomer Compounds with the same molecular formula and the same 
structural formula but different from each other in their three-
dimensional configuration of their atoms in space. 
Stereoselectivity The preferential formation in a chemical reaction of one 
stereoisomer over another.  When stereoisomers are enantiomers, 
the phenomenon is called enantioselectivity and is quantitatively 
expressed by the enantiomer excess.  When they are 
diastereomers, it is called diastereoselectivity and is quantitatively 
expressed by the diastereomer excess. 
Stereospecificity A reaction is termed stereospecific if starting materials differing 
only in their configuration are converted into stereoisomeric 
products.  According to this definition, a stereospecific process is 
necessarily stereoselective but not all stereoselective processes 
are stereospecific. 
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KESPESIFIKAN ENANTIOMER ANTIBODI POLIKLONAL 
YANG DIBANGUNKAN TERHADAP ENANTIOMER RASEMIK 
DAN ENANTIOMER TULEN SALBUTAMOL SERTA IMPLIKASI 
PENGGUNAANNYA DALAM IMUNOASAI ENZIM 
 
ABSTRAK 
Salbutamol (albuterol) adalah agonis β2-adrenergik yang popular digunakan dalam rawatan 
asma dan gangguan obstruktif pulmonari kronik (COPD).  Salbutamol biasanya 
disalahgunakan sebagai peningkat prestasi dalam sukan serta penggalak tumbesar yang 
berkesan pada ternakan.  Pengawasan terhadap penyalahgunaan salbutamol bergantung 
kepada kejayaan pelaksanaan kaedah penapisujian air kencing untuk mengesan bahan 
tersebut di mana immunoasai enzim memainkan peranan penting.  Oleh kerana 
kecenderungan untuk menukar kepada enantiomer tunggal sebagai ajen terapeutik yang lebih 
selamat dan berkesan, (R)-salbutamol telah diperkenalkan untuk kegunaan terapeutik pada 
manusia serta sebagai penggalak tumbesar dalam perubatan veterinar.  Pertukaran ini 
menimbulkan tanda tanya tentang penggunaan imunoasai tradisional yang menggunakan 
antibodi rasemik (RS)-salbutamol.  Kereaktifan-silang dan keterpilihan-enantio antibodi 
menggunakan immunogen yang disintesiskan melalui kaedah campuran anhidrid (MA) dan 
pengaktifan epoksi (BDDE) pada arnab, telah dikaji.  Antibodi-antibodi menunjukan 
keterpilihan-enantio samaada terhadap (R)-salbutamol atau (S)-salbutamol bergantung 
kepada individu haiwan, jadi antibodi-antibodi ini tidak sesuai digunakan dalam pemantauan 
aras (R)-salbutamol.  Sehubungan itu, tiga jenis antibodi enantio-khusus menggunakan (R)- 
dan (S)-salbutamol sebagai hapten juga telah dihasilkan.  Antibodi (R)-salbutamol 
menunjukkan kereaktifan-silang sebanyak 3.94-7.13% terhadap antipodnya.  Manakala 
antibodi (S)-salbutamol menunjukkan kereaktifan silang sebanyak 3.28-5.25% terhadap 
enatiomer-(R).  Antibodi-antibodi ini berpotensi digunakan untuk pemantauan aras setiap 
individu enantiomer dalam air kencing.  Sampel air kencing khinzir yang dianalisis 
menggunakan kaedah ELISA  menunjukkan 17.71% sampel positif palsu dan 0% sampel 
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negatif palsu, apabila dibandingkan dengan kaedah kiral LC-MS/MS yang disahkan.  Sampel 
positif air kencing khinzir didapati kandungan utmanya adalah (S)-salbutamol, sekaligus 
mencadangkan bahawa penyingkiran salbutamol adalah secara stereo-terpilih kepada (S)-
salbutamol.  Empat sampel air kencing dari ekuin (kuda) dan dua sampel dari manusia yang 
dikenalpasti positif mengandungi salbutamol juga dianalisa.  Keputusan menunjukkan proses 
metabolisme utama salbutamol pada ekuin adalah melalui proses glukuronidasi, manakala 
pada manusia melalui proses sulfasi.  Metabolit glukuronida dan sulfat diasingkan daripada 
air kencing ekuin dan manusia, masing-masing.  Metabolit sulfat sangat rintang terhadap 
hidrolisis enzim β-glukuronidase/arilsulfatase dan keadaan piawai hidrolisis asid.  Sejumlah 
metabolit sulfat diasingkan dari sel HepG2 yang dieramkan dengan salbutamol.  Metabolit 
glukuronida dan sulfat yang diasingkan kemudiannya digunakan untuk mencirikan 
kereaktifan-silang antibodi rasemik salbutamol.  Kereaktifan-silang antibodi terhadap 
glukuronida adalah 358.06% dan 227.26% untuk kedua-dua antibodi MA dan BDDE, 
masing-masing.  Walau bagaimanapun, kereaktifan-silang antibodi-antibodi tersebut 
terhadap metabolit sulfat adalah jauh lebih rendah iaitu sebanyak 20.72% dan 23.81% bagi 
kedua-dua antibodi MA dan BDDE.  Penemuan mengenai metabolit ini menimbulkan 
pertanyaan tentang kajian farmakologi dan analitikal sebelumnya yang mengandaikan 
bahawa metabolit sulfat salbutamol dihidrolisiskan sepenuhnya oleh enzim β-
glukuronidase/arilsulfatase dan kereaktifan-silang metabolit-metabolit adalah 100% dengan 
antibodi poliklonal. 
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ENANTIOSPECIFICITY OF POLYCLONAL ANTIBODIES 
RAISED AGAINST RACEMIC AND PURE ENANTIOMERS OF 
SALBUTAMOL AND THE IMPLICATIONS OF THEIR USE IN 
ENZYME IMMUNOASSAY 
 
ABSTRACT 
Salbutamol (albuterol) is a β2-adrenergic agonist popularly used in the treatment of asthma 
and chronic obstructive pulmonary disorder (COPD), and is also commonly abused as a 
performance enhancer in sports as well as an effective growth promoter in livestock.  The 
monitoring of salbutamol abuse relies on the successful implementation of urinary screening 
methods to detect the substance of which enzyme immunoassay plays an important role.  
With the trend to switch to single enantiomers as safer and more effective therapeutic agents, 
(R)-salbutamol has been introduced for use in human therapeutics as well as in veterinary 
medicine as a growth promoter.  This switch calls into question the usefulness of traditional 
salbutamol immunoassays which use antibodies based on a racemic (RS)-salbutamol.  The 
cross-reactivity and enantioselectivity of antibodies using immunogens synthesized via the 
mixed anhydride (MA) and epoxy activation (BDDE) methods in rabbits were investigated.  
The antibodies showed enantioselectivity either towards (R)-salbutamol or (S)-salbutamol 
depending on the individual animal and these antibodies are not ideal to monitor (R)-
salbutamol levels.  Three types of enantiospecific antibodies using (R)- and (S)-salbutamol 
as hapten were also raised.  The (R)-salbutamol antibodies displayed cross-reactivity of 3.94-
7.13% towards the antipode.  The (S)-salbutamol antibodies showed 3.28-5.25% cross-
reactivity towards the (R)- enantiomer.  These antibodies would be potentially useful to 
monitor the individual enantiomer levels in urine.  Porcine urine samples analysed using the 
ELISA method demonstrated 17.71% false positives and 0% false negative when compared 
to a validated chiral LC-MS/MS method.  The positive porcine urine samples showed 
predominance of (S)-salbutamol concentration suggesting that the free drug clearance is 
stereoselective for (S)-salbutamol.  Four known positive equine and two known human 

positive samples were also analysed.  The results revealed that equine metabolism is 
principally via glucuronidation and that the human is mainly via sulphation.  The 
glucuronide and sulphate metabolites were isolated from equine and human urine 
respectively.  The sulphate metabolite was extremely resistant towards hydrolysis by β-
glucuronidase/arylsulphatase and standard acid hydrolysis conditions.  Quantifiable amounts 
of the sulphate metabolite were isolated from HepG2 cells incubated with salbutamol.  The 
isolated glucuronide and sulphate metabolites were then used to characterize the cross-
reactivity of the racemic salbutamol antibodies.  The cross-reactivities against the 
glucuronide were 358.06% and 227.26% for the MA and BDDE antibodies respectively.  
However, the cross-reactivity for the sulphate was much lower at 20.72% and 23.81% for the 
MA and BDDE.  These findings on the metabolites raises questions on previous 
pharmacological, and analytical studies which had assumed that the sulphate metabolite to 
be fully hydrolysed using β-glucuronidase/arylsulphatase and the cross-reactivities of the 
metabolites to be 100% with the polyclonal antibodies. 

CHAPTER 1: 
INTRODUCTION 
 
 
1.1 A brief history of salbutamol 
Salbutamol (Albuterol) is chemically known as 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-
(hydroxymethyl)phenol (Figure 1.1).  To date, it is the most popular bronchodilator drug 
used for the treatment of asthma and better known by its brand name, Ventolin. 
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Figure 1.1: The molecular structure of salbutamol (albuterol) or chemically known as 4-[2-(tert-
butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol.  The chiral centre of the molecule 
is marked with *. 
Salbutamol was first invented by David Jack and his team of researchers in 1966 and 
patented by Allen and Hansburys (Glaxo Group Research) in 1969 (Marasco, 2005) in 
response to finding a solution for the increasing mortality rate by isoprenaline users in the 
1960s.  The introduction of isoprenaline in aerosol form then, caused an estimated 3,000 
deaths among asthmatic teenagers in the United Kingdom (Sneader, 2005).  Their objective 
of producing a stable, safer, and long-acting analogue of isoprenaline led to the development 
of saligenin and then salbutamol.  Salbutamol fulfilled their objectives as a longer-acting 
bronchodilator that acted selectively on bronchial muscle with minimal cardiovascular 
adverse effects (Cullum et al., 1969; and Kennedy and Simpson, 1969). 
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1.2 Chemistry 
Salbutamol is one of the bronchodilators grouped as β-agonists or phenethanolamine β-
adrenergic agonists.  These group of drugs conform to the general structure of a six-
membered aromatic ring with hydroxyl group(s) bound to the β-carbon, nitrogen that is 
positively charged at physiological or acidic pH found in the ethylamine side chain, and 
bulky substituent (marked as R; Figure 1.2) on the aliphatic nitrogen (Figure 1.4).  The 
specificity of the drugs for the β-adrenoceptor is marked by the bulky substituent (Weiner, 
1980).  As such this bulky substituent is not only to β-agonists but also the endogenous 
adrenergic neurotransmitters epinephrine and norepinephrine (Figure 1.3; Smith, 1998). 
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Aromatic Substitution Category Examples A B C 
-H -OH -H Phenol Ractopamine 
Ritodrine 
-OH -H -OH Resorcinol Fenoterol 
Terbutaline 
-OH -OH -H Catechol Isoproterenol 
Dobutamine 
-CH2OH -OH -H Saligenin Salbutamol 
Salmeterol 
Figure 1.2: The general structure of a phenethanolamine β-agonist and a list of the common 
substitution groups found on the aromatic ring and the bulky substituent (R) on the 
aliphatic nitrogen.  The R group is usually a t-butyl group, isopropyl group, alkylphenyl, or 
alkylphenol.  The para- (p-) and meta (m-) positions on the aromatic ring relative to the 
phenethanolamine β-carbon are marked (adapted from Smith, 1998). 
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Figure 1.3: The molecular structures of the endogenous adrenergic neurotransmitters: i) epinephrine 
and ii) norepinephrine. 
 
 
Table 1.1: The analogues of phenethanolamine β-adrenergic agonists grouped according to their 
categories. 
Category Drug name Structure 
Phenol Ractopamine 
OH
OH
NH
CH3
OH
 
 Ritodrine OH
OH
NH
CH3
OH
 
Resorcinol Fenoterol 
OH
NH
CH3
OH
OH
OH
 
 Terbutaline 
OH
OH
NH
OH
CH3
CH3
CH3
 
Catechol Isoproterenol OH
NH
OH
OH CH3
CH3
 
 Dobutamine OH
NH
OH
OH
CH3
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Table 1.1: Continued. 
Category Drug name Structure 
Saligenin Salbutamol 
NH
OH
CH3
CH3
CH3
OH
OH
 
 Salmeterol 
OH
NH
OHOH
O
 
 Pirbuterol 
N NH
OH
CH3
CH3
CH3
OH
OH
 
Monophenols Bamethan 
NH
OH
OH
CH3
 
 Carbuterol 
NH
OH
CH3
CH3
CH3
OH
NH
NH2O
 
 Isoxsuprine OH
OH
NH
CH3
O
CH3
 
Miscellaneous Clenbuterol 
Cl
Cl
NH
OH
CH3
CH3
CH3
NH2
 
 Mabuterol 
Cl
NH
OH
CH3
CH3
CH3
NH2
F
F
F

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Salbutamol (Figure 1.1) with a molecular weight of 239.31, is usually prepared in the form 
of a sulphate salt named salbutamol sulphate (molecular weight 576.70).  It is approximately 
11 Å long (Smith, 1998) with almost white crystalline powder that is freely soluble in water 
but not methylene chloride or ethanol (British Pharmacopoeia, 2012).  The aliphatic amine 
present gives it pKa values of 9.3 and 10.3 (Smith, 1998; and Shen et al., 2012).  A single 
chiral centre gives rise to two enantiomers: (R)-salbutamol and (S)-salbutamol (Figure 1.4).  
Planar polarised light rotation found that (R)-salbutamol had the (-)- configuration and (S)-
salbutamol the (+)- orientation (Hartley and Middlemiss, 1971).  However, current 
therapeutic drug preparations are racemates (equal proportion of both enantiomers), with the 
exception of Xopenex® which constitutes only (R)-salbutamol as its active ingredient. 
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Figure 1.4: Molecular structure of i) (R)-salbutamol and ii) (S)-salbutamol.  The chiral centre is 
marked with *. 
 
 
 
1.3 Pharmacology 
The bronchodilator group of drugs called β-agonists is made up of salbutamol, clenbuterol, 
terbutaline, salmeterol, formoterol, ractopamine, cimaterol, and many others.  They act upon 
the β2-adrenoceptors in the smooth muscles of the bronchial airways to bring about 
bronchodilation.  These drugs are grouped into short- and long-acting β-agonists.  Short-
acting β-agonists exert their effects immediately within 3-5 minutes and last for 4-6 hours, 
whereas long-acting β-agonists are maintenance drugs lasting 12 hours.  The long-acting β-
agonists wield their effects 20 minutes after administration and its 12 hour protection allow 

people with chronic obstructive pulmonary disease (COPD) to sleep better at night albeit less 
frequent usage (Table 1.2; American Thoracic Society). 
 
Bronchodilators mimic the actions of sympathetic adrenergic stimulation acting through β-
adrenoceptors.  Activation of these receptors relaxes the bronchial smooth muscles, 
stimulates glycogenolysis in the liver, release rennin from the kidneys, and increases heart-
rate.  The β-adrenoceptor embedded in the cell plasma membrane is a single polypeptide 
glycoprotein moiety.  It exists as three subtypes: β1 (cardiac tissues), β2 (respiratory tract), 
and β3 (found on adipose tissues) (Fernandes et al., 2004).   
 
Beta-agonists interact with the β2-adrenoceptors on the smooth muscle tissues and 
subsequently activate the intracellular signalling cascade through the membrane bound 
adenylyl cyclase enzyme (Johnson, 2001).  Upon activation of the receptor, adenylyl cyclase 
through the guanine nucleotide regulatory protein (Gs) converts adenosine-5’-triphosphate 
(ATP) to cyclic adenosine-3’,5’-monophosphate (cAMP).  The cAMP is an intracellular 
messenger that regulates cellular functions such as muscle relaxation or contraction by 
modifying cAMP-dependent protein kinases.  Phosphorylation of the myosin light chain 
kinase prevents interaction of the contractile protein myosin resulting in smooth muscle 
relaxation.  Moreover, cAMP also decreases muscle contraction by inhibiting the influx of 
calcium via the voltage dependent calcium channels (Fernandes et al., 2004). 
 
The β-agonists aromatic ring substituted with hydroxyl groups, halogens, amines, 
hydroxymethyl groups, and cyano groups, is the key to elicit receptor binding for executing 
their biological activity.  The substitution groups then dictate the compound half-life and 
efficacy at the receptors (Smith, 1998).  Eason and Stedman (1933) proposed that β-
adrenoceptors interact with β-agonists at three sites on the molecule: the β-hydroxyl group, 
the aliphatic nitrogen, and the aromatic ring.  The hypothesis was validated and it was found 
that β2-adrenoceptors cloned from human, mouse, and rat are 87-93% similar in amino acid 

make-up (Hieble et al., 1995).  Hydrophilic and hydrophobic amino acids distribution in the 
β2-adrenoceptor primary sequence is similar to that of rhodopsin.  Rhodopsin, a visual seven-
transmembrane protein, has the amino and carboxyl groups extended into the extracellular 
space and cytoplasm respectively.  Amino acids spanning the cell membrane are arranged in 
α-helical orientation around a ‘pore’ where receptor ligands bind (Hieble et al., 1995). 
 
At physiological pH values, salbutamol gets protonated at the aliphatic amine.  This enables 
the molecule to interact with the carboxyl extensions of the β2-adrenoceptor in a ligand-
receptor interaction.  The aromatic ring and cathecholhydroxyl groups form hydrogen 
bonding with serine204 (Ser204) and Ser207 on the fifth transmembrane helix, thus increasing 
the binding affinity of ligand-receptor (Hieble et al., 1995).  Consequently, salbutamol if not 
ionized at the receptor will fail to exert its activity without the ligand-receptor interaction. 
 
 
1.3.1 Pharmacokinetics 
Pharmacokinetics describes the time course of drug concentrations in the body and it 
involves the processes of absorption (method of drug administration), distribution 
(disbursement of drug to body tissues), metabolism (biotransformation of drugs into 
metabolites), and excretion (removal of drug and metabolites from the body system) of 
primarily drug substance or abbreviated as ADME. 
 
1.3.1(a)  Absorption 
Beta-agonists are usually administered by inhalation, oral, and intravenous methods.  In 
humans, salbutamol is more commonly prescribed in the form of inhalation.  This method of 
drug administration allows limited access to the lungs but produces immediate and effective 
bronchodilation effect (Morgan, 1990).  A high proportion of inhaled drugs is swallowed and 
gets metabolized in the gut.  They are rapidly absorbed through the lungs and gastrointestinal 
tract (small intestine).  Most of the β-agonists reach maximum plasma concentration within 
	
1-3 hours post oral administration in humans (Morgan, 1990) with the exception of halogen-
substituted aromatic ring β-agonists such as clenbuterol and mabuterol.  They reach peak 
plasma concentration 4 hours after oral dosing due to drug accumulation (Meyer and Rinke, 
1991).   
Table 1.2: A list of short- and long-acting β-agonists with their respective brand names, method of 
administration, and dosage form.  Dosages may vary with generic products.  [MDI 
(Metered dose inhaler) in the form of aerosol/spray].  [DPI (Dry powder inhaler) the 
number of ‘puffs’ needed depends on the success of entire dose inhalation by the person].  
Adapted from American Thoracic Society [Online].  Date accessed: 7 May 2014.  
(https://www.thoracic.org/clinical/copd-guidelines/for-patients/what-kind-of-medications-
are-there-for-copd/what-are-beta-agonists.php).  
Drug name Brand name Method of 
administration Dosage 
Short-acting β-agonists 
Salbutamol 
(Albuterol) 
Airolin® 
Airomir® 
Asmasal® 
Buventol® 
Inspiryl® 
Proventil® 
 
 
 
 
 
Salamol® 
Salbulin® 
Salbutamol® 
Ventodisk® 
Ventolin® 
 
 
 
 
 
Ventolin 
Evohaler® 
MDI 
MDI 
DPI 
DPI 
DPI 
MDI 
DPI 
Tablets 
Liquid for nebulizer 
 
 
MDI 
MDI 
MDI 
DPI 
MDI 
DPI 
Tablets 
Liquid for nebulizer 
 
 
MDI 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
4-8 mg every 12 hours 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
1 puff every 4-6 hours 
2-4 mg every 6-8 hours 
0.25-0.5 mL of 0.5% 
solution in nebulizer every 
4-6 hours 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
1-2 puffs every 4-6 hours 
1 puff every 4-6 hours 
2-4 mg every 6-8 hours 
0.25-0.5 mL of 0.5% 
solution in nebulizer every 
4-6 hours 
1-2 puffs every 4-6 hours 
Bambuterol Bambec® Tablets 10-20 mg every night 
Fenoterol Berotec® MDI 
DPI 
Liquid for nebulizer 
1-2 puffs 2-3 times daily 
1 puff 2-3 times daily 
0.2-0.4 mL with normal 
saline every 4-6 hours 
Isoetherine Bronkosol® 
 
Bronkometer® 
Liquid for nebulizer 
 
MDI 
0.25-0.5 mL in nebulizer 
with 2 mL normal saline 
2 puffs every 4 hours 


Table 1.2: Continued. 
Drug name Brand name Method of 
administration Dosage 
Isoproterenol 
(Isoprenaline) 
Isuprel® MDI 
Liquid for nebulizer 
1-2 puffs every 4-6 hours 
0.25-0.5 mL with 2 mL 
normal saline 
Levalbuterol  
[(R)-salbutamol] 
Xopenex® Liquid for nebulizer 0.63-1.25 mg every 6-8 
hours 
Metaproterenol Alupent® 
 
 
 
Metaprel® 
ProMeta® 
MDI 
Tablets 
Liquid for nebulizer 
 
Liquid for nebulizer 
 
MDI 
Liquid for nebulizer 
 
1-2 puffs every 4 hours 
20 mg every 6-8 hours 
0.2-0.3 mL 5% solution in 
nebulizer 3-4 times daily 
0.2-0.3 mL 5% solution in 
nebulizer 3-4 times daily 
1-2 puffs every 4 hours 
0.2-0.3 mL of 5% solution 
3-4 times daily 
Pirbuterol Maxair® MDI/autoinhaler 1-2 puffs every 4-6 hours 
Terbutaline Breathaire® 
Brethine® 
 
 
 
Bricanyl® 
Tablets 
MDI 
DPI 
Tablets 
Liquid for nebulizer 
MDI 
DPI 
Tablets 
Liquid for nebulizer 
2.5-5 mg every 8 hours 
1-2 puffs every 4-6 hours 
1 puff every 4-6 hours 
2.5-5 mg every 8 hours 
5 mg up to 4 times daily 
1-2 puffs every 6-8 hours 
1 puff every 6 hours 
2.5-5 mg every 8 hours 
5 mg every 6-8 hours 
Tornalate Bitolerol® MDI 
Liquid for nebulizer 
1-2 puffs every 8 hours 
0.5-1 mL 3-4 times daily 
 
Long-acting β-agonists 
Formoterol Foradil® 
Oxis® 
DPI 
DPI 
1 puff every 12 hours 
1-2 puffs every 12 hours 
Salmeterol Serevent® MDI 
DPI 
2 puffs every 12 hours 
1 puff every 12 hours 
 
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1.3.1(b) Distribution 
Drugs absorbed into the bloodstream are reversibly distributed to the body tissues through 
the physicochemical interaction of the drug molecules with the tissue.  Drug distribution is 
indicated by the volume of distribution (Vd).  A high Vd value shows that the drugs are 
widely distributed throughout body tissues resulting in low plasma concentrations and vice 
versa.  Drug distribution is characteristic of the individual drug molecule itself that is usually 
reflective of the physicochemical property of the molecule.  More lipid soluble drugs tend to 
have higher volume of distributions e.g. steroids have large Vd values whereas drugs like 
caffeine and ibuprofen have small Vd values (Lombardo et al., 2004; and Ghafourian et al., 
2006). 
 
Salbutamol has total plasma clearance of 480 + 123 mL/min and Vd of 156 + 38 L (Morgan 
et al., 1986).  Salbutamol with a pKa of 9.3 gets protonated at physiological pH of 7.4.  Thus, 
this ensures that this molecule remains in circulation (tissue extracellular compartment) and 
does not partition into the adipose tissues.  Moreover, the length of the aliphatic side chain is 
insufficient to incorporate lipid-soluble characteristics (Johnson, 1995; and Smith, 1998).  
This feature allows for less residue accumulation in adipose tissues.  Thus, it maybe safer for 
use in livestock growth enhancement compared with the more lipophilic β-agonist, 
clenbuterol.  The halogen substitution on the aromatic ring improves the lipophilicity of 
clenbuterol (Smith, 1998). 
 
1.3.1(c)  Metabolism 
Metabolism of a drug is a biotransformation process to enable drug clearance from the 
system in the presence of an enzyme, thus producing a more hydrophilic product 
(metabolite).  This process involves modifications via oxidation, reduction, hydrolysis, 
hydration, conjugation, and condensation reactions which ultimately determine the 
pharmacological and/or toxicological output (Gibson and Skett, 2001).  Drug metabolism is 
divided into two phases: i) phase I (functionalisation reactions) and ii) phase II (conjugative 

reactions).  Phase I metabolism is usually assumed to ‘functionalise’ the parent drug in 
preparation for phase II conjugation metabolism by activation, addition or removal of 
functional group suitable for phase II conjugation (Table 1.3).   
Table 1.3: The categorization of reactions involved in phase I and phase II metabolism.  Adapted from 
Gibson and Skett (2001). 
Phase I metabolism reactions Phase II metabolism reactions 
Oxidation 
Reduction 
Hydrolysis 
Hydration 
Dethioacetylation 
Isomerisation 
Glucuronidation/glucosidation 
Sulphation 
Methylation 
Acetylation 
Amino acid conjugation 
Glutathione conjugation 
Fatty acid conjugation 
Condensation 
Phase I metabolism 
The phase I metabolism takes place mainly in the endoplasmic reticulum where reduction, 
hydration, and two types of oxidation can occur: 
i. Hydroxylation (incorporation of oxygen into the drug molecule) 
ii. Oxidative, deamination, and dealkylation (loss of functional groups) 
 
The sole purpose of oxidation is to insert an oxygen atom into the complex substrate 
molecule for the next phase metabolism or excretion.  Reductive mechanism catalyses azo-
compounds, nitro-compounds, epoxides, heterocyclic ring compounds, and halogenated 
hydrocarbons in the presence of hepatic microsomal enzymes.  Hydrazide and carbamate 
hydrolysis are some examples of reduction metabolism.  Hydration is a reaction that adds 
water to a compound without causing dissociation of the compound.  This is achieved with 
the assistance of epoxide hydrolase enzyme where epoxides are hydrated to form 
dihydrodiol. 

The most important oxidation reaction occurs with the microsomal cytochrome P450 system 
(mixed-function oxidases).  It facilitates reactions such as aromatic hydroxylation, aliphatic 
hydroxylation, epoxidation, N-dealkylation, O-dealkylation, S-dealkylation, oxidative 
deamination, N-oxidation, S-oxidation, phosphotionate oxidation, dehalogenation, and 
alcohol oxidation.  Other non-mixed-function oxidase enzymes also involved with phase I 
metabolism are alcohol dehydrogenase, aldehyde dehydrogenase, xanthine oxidase, amine 
oxidases, aromatases, and alkylhydrazine oxidase (Gibson and Skett, 2001).   
 
Phase II metabolism 
Phase II metabolism utilizes a wide array of enzymes for conjugation reactions that produces 
more water-soluble products which can be excreted in bile or urine (Table 1.4).  
Glucuronidation is the main route of conjugation due to the abundant availability of the 
reaction co-factor, uridine-5’-diphospho (UDP)-glucuronic acid and the enzyme, UDP-
glucuronosyltransferase.  This conjugation is suitable for compounds containing functional 
groups like alcohols, phenols, hydroxylamines, carboxylic acids, amines, sulphonamides, 
and thiols.  There are two types of glucuronides produced: O-glucuronide and N-
glucuronide.  Compounds with groups like phenols, alcohols, and carboxylic acids form the 
‘ester’ or ‘ether’ O-glucuronides.  There is a common observation that inversion takes place 
in compound reaction with the α-glucuronic acid resulting in the formation of a β-
glucuronide metabolite.  They are excreted into hepatic bile and can be hydrolysed by 
endogenous β-glucuronidase enzyme to its parent compound which will then be reabsorbed 
through the intestinal mucosa.  This recycling of drugs is termed ‘enterohepatic circulation’.  
N-glucuronides on the other hand reacts mainly with aromatic amines, amides, and 
sulphonamides.  Other less common forms of glucuronides are S-glucuronides (from thiol 
groups) and C-glucuronides (direct attachment of glucuronic acid to the carbon skeleton) 
(Gibson and Skett, 2001). 
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Table 1.4: Conjugation reactions and the relevant enzymes involved in the cytoplasm phase II 
metabolism (adapted from Gibson and Skett, 2001). 
Reaction Enzyme Functional group 
Glucuronidation 
Glycosidation 
Sulphation 
Methylation 
Acetylation 
Amino acid conjugation 
Glutathione conjugation 
Fatty acid conjugation 
Condensation 
UDP-Glucuronosyltransferase 
UDP-Glycosyltransferase 
Sulphotransferase 
Methyltransferase 
Acetyltransferase 
 
Glutathione S-transferase 
-OH; -COOH; -NH2; -SH 
-OH; -COOH; -SH 
-NH2; -SO2NH2; -OH 
-OH; -NH2 
-NH2; -SO2NH2; -OH 
-COOH 
Epoxide; organic halide 
-OH 
Various 
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Figure 1.5: The structure of 3’-phosphoadenosine-5’-phosphosulphate (PAPS). 
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Adenosine-5'-phosphosulphate (APS) + PPi
 
APS + ATP 
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3'-phosphoadenosine-5'-phosphosulphate (PAPS) + ADP
 
Figure 1.6: A two stage adenosine triphosphate (ATP) reaction with sulphate to form energy rich 3’-
phosphoadenosine-5’-phosphosulphate (PAPS) for phase II sulphation metabolism (adapted 
from Gibson and Skett, 2001). 
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Sulphation is another major metabolic reaction for phenols taking place in the cytosol.  It can 
also occur for alcohols, amines, although less for thiols.  In this reaction, 3’-
phosphoadenosine-5’-phosphosulphate (PAPS) (Figure 1.5) which acts as an energy rich 
donor is obtained through a two-stage reaction from adenosine-triphosphate (ATP) and 
sulphate (Figure 1.6) (Gibson and Skett, 2001).  Interaction of PAPS and cytosolic 
sulphotransferase (SULT) enzyme produces sulphate conjugated metabolites. 
 
Although salbutamol is well-absorbed orally in humans, it has low bioavailability as a result 
of extensive first-pass-metabolism.  Salbutamol undergoes phase II metabolism to form two 
main metabolites namely salbutamol-3-O-glucuronide and salbutamol-4-O-sulphate (Walle 
et al., 1996; and Mareck et al., 2011) with the metabolites formed varying across species. 
 
Glucuronidation of the salbutamol aromatic hydroxyl group inhibits pharmacological 
exertion, thus rendering the resultant metabolite inactive (Morgan, 1990; and Smith, 1998).  
In the presence of microsomal enzyme, UDP-glucuronosyltransferase, salbutamol is 
conjugated to UDP-glucuronic acid to form salbutamol-3-O-glucuronide (Figure 1.7).  
Angus et al., (1989) proved through perfused rat liver that extreme hypoxia is needed to 
produce significant impairment of the glucuronidation-dependent elimination of salbutamol. 
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Figure 1.7: Phase II glucuronidation metabolism of salbutamol catalyzed by UDP-
glucuronosyltransferase with UDP-glucuronic acid (UDPGA) as a high energy donor to 
form salbutamol-3-O-glucuronide. 
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Sulphotransferases (SULT) in the liver, small intestine, stomach, kidneys, and colon 
catalyzes sulphate conjugation of endogenous compounds and drugs to render them 
biologically inactive (Lin et al., 2011).  The principal salbutamol metabolite in human is 
salbutamol-4-O-sulphate formed by sulphate conjugation to the phenolic moiety, is carried 
out by the active M form of human cytosolic phenolsulphotransferase (PST) enzyme (Walle 
et al., 1993a; and Dong et al., 2011) or more specifically the SULT1A3 (Ko et al., 2012) 
using the nucleophilic substitution reaction (Figure 1.8).  Its sulphotransferase-mediated 
metabolism is most effective at pH 9.0. 
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Figure 1.8: In a nucleophilic substitution reaction, the phenolic moiety of salbutamol is catalyzed to 
form the biologically inactive metabolite salbutamol-4-O-sulphate.  The reaction is aided 
by the cytosolic phenolsulphotransferase (PST) enzyme found in the liver, small intestine, 
kidneys, stomach, and colon (adapted from Walle et al., 1996; and Dong et al., 2011). 
Salbutamol clearance from the human body depends primarily on its sulphate conjugation 
(Eaton et al., 1996).  The insignificant protein binding of salbutamol helps to facilitate its 
excretion from the kidneys.  For intravenous salbutamol administration, 64.2% is excreted in 
the unconjugated form whilst 12% is excreted as the sulphate conjugate.  Oral administration 
differs from the intravenous administration where 31.8% is excreted in the unchanged form 
whereas 48.2% is excreted as sulphated metabolites (Morgan et al., 1986).   
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1.3.1(d) Excretion 
Excretion is the final pharmacokinetic phase that deals with the removal of drug and its 
metabolite(s) from the body system.  Unconjugated drug and its metabolites are excreted 
from the body system mainly via the liver and kidneys where hydrophilic substances are 
eliminated faster than the lipophilic ones (Dong et al., 2011).  Total renal excretion involves 
glomerular filtration, active tubular excretion, and passive tubular re-absorption.  The 
glomerular filtration allows unconjugated drug and its metabolites to filter through its pores 
to be eliminated depending on the efficiency of renal blood flow.  Active transporters (P-
glycoprotein, multidrug resistance-associated proteins, and organic anion and cation 
transporters) aid ionised compounds such as salbutamol-4-O-sulphate and salbutamol-3-O-
glucuronide to be excreted through the renal tubules (Morgan et al., 1986; Moaddel et al., 
2005; and Dong et al., 2011).  This process is influenced by the plasma pH values that affect 
the ionization of the compounds to be transported.  The passive tubular re-absorption 
involves the re-uptake of non-ionized compounds by way of concentration gradient that is 
also pH dependent (Dong et al., 2011). 
 
 
 
1.4 Therapeutic uses of salbutamol 
Asthma is an age old respiratory disease characterized by inflamed and swelling of the 
airways leading to bronchoconstriction that is sensitive to irritants and susceptible to allergic 
reactions.  The victims perpetually experience bouts of coughing spells at night or in the 
early mornings.  They show symptoms such as wheezing, chest tightness, difficulty in 
breathing, and coughing.  An estimated 315 million people worldwide are asthmatics (To et 
al., 2012) and there is no known cure (Marasco, 2005) although it can be managed with the 
use of β-agonists.  Beta-agonists are bronchodilators developed to combat asthma attacks 
and bring quick relief to the victim.  It is usually administered through inhalation for 
immediate relief or in the form of oral tablets and even via intravenous injections.   
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1.5 Adverse effects of salbutamol 
The toxicity of salbutamol/β-agonists is marked by clinical symptoms like headache, nausea, 
dizziness, palpitation, tachycardia, peripheral vasodilatation, nervousness, tremors, fever, 
chills, and breathing irregularities in acute cases (Sheu et al., 2009).  Non-β2-
bronchoconstriction that counter the therapeutic effects have been attributed to be due to the 
(S)-salbutamol (Lipworth et al., 1997; and Pesola and D’Costa, 2003). 
 
 
1.6 Stereochemistry and stereoselective pharmacology 
1.6.1 Chirality 
Recent advances in analytical and synthetic chemistry have led to a better understanding of 
the differences in biological activities of enantiomers.  Chiral molecules are usually 
asymmetrical with reference to the tetrahedral carbon atom that has four different 
atoms/groups bound to it (Figure 1.9 i).  This carbon atom is called centre of asymmetry or 
chiral centre.  Atoms such as nitrogen, sulphur, and phosphorus are also able to form 
pharmacologically important chiral molecules with four different groups bound to them in 
tetrahedral configuration (Figure 1.9 ii) (Allenmark, 1988). 
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Figure 1.9: Structures in i) are a pair of enantiomers showing an asymmetric tetrahedral carbon and ii) 
examples of other atoms (sulphur, nitrogen, and phosphorus) that constitute a chiral centre. 
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Chirality derived from the Greek word ‘kheir’ (χειρ) meaning ‘hand’, refers to a subject in 
chemistry relating to structures that is non-superimposable with its own mirror image (Eliel 
and Wilen, 1994).  Molecule without this unique feature is termed ‘achiral’.  This led to the 
three dimensional study on atoms and/or groups absolute configuration/orientation in space 
within a molecule termed stereochemistry (Lin et al., 2011).  Interest in stereochemistry 
began with the discovery of plane polarised light rotation in quartz and later tartaric acid by 
Malus in 1809 (Nagendrappa, 2007; and Lin et al., 2011). 
 
The study of chirality progressed with Louis Pasteur’s observation of chirality (tartaric acid 
found in the sediments of fermenting wine) in both crystalline and solution form.  It was an 
era where optical activity was characteristic of crystal (i.e. sodium chlorate and sodium 
bromate) but not solutions.  Under the microscope, Pasteur observed that the tartaric acid 
crystals formed were almost identical and non-superimposable mirror images of each other.  
Pasteur separated the crystals manually and dissolved them in separate solutions.  He found 
that one of the tartaric acid solutions polarised light to the left [(-)-tartrate] and another to the 
right [(+)-tartrate].  Thus, he concluded that optical activity was characteristic of the 
individual (-)- and (+)- molecules and not superimposable with their mirror images (Tan, 
1996).  They were termed enantiomorphs or enantiomers (Eliel and Wilen, 1994).  
Subsequently, Irish physicist William Thomson (Lord Kelvin) coined the name ‘chirality’ 
following Louis Pasteur’s discoveries.  Although chirality is found also across an axis or a 
plane, but few such chiral compounds are of pharmacological importance. 
 
 
1.6.2 Stereoselectivity in pharmacology 
Natural biological building blocks (i.e. proteins, enzymes, and receptors) are invariably 
chiral molecules derived from L-amino and D-carbohydrates.  As such, interactions between 
a chiral biological macromolecule and an enantiomeric pair are essentially different and they 
are viewed as two different chemical entities.  The resultant observation is usually an 

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enhanced biological/pharmacological activity residing in one of the enantiomers due to their 
affinity and contact with endogenous proteins, enzymes, and receptors.  Thus, chirality is 
important to gauge drug efficacy.  According to the Easson and Steadman model (Patil et al., 
2008) the more potent compound possesses the stronger interaction or better fitting with 
receptors.  Consequently, the enantiomer that illicit better affinity or pharmacological 
activity is termed the eutomer whereas its lower affinity counterpart the distomer.  Both 
enantiomers show differences in pharmacodynamics and pharmacokinetics.  However, it is 
known that drug molecules and their complementary receptor are able to undergo 
conformation changes when in contact (Albert, 1985).  Their eudismic ratios measure their 
stereoselective receptor-mediated activation (Patil et al., 2008).   
 
The importance of chiral drugs has gained more recognition with better understanding of the 
individual enantiomer biological activities.  Studies conducted prove that the 
pharmacological and toxicological properties of a racemic drug are not equivalent to the 
simple sum of contribution from both enantiomers.  Their activities are complex and their 
pharmacological inputs vary according to their chemical entity.  Utilising both enantiomers 
in the dosage form without understanding the pharmacological and toxicological 
implications of each enantiomer is risky.  A variety of differential enantiomer contributions 
to pharmacological effects are known and are outlined below. 
 
1.6.2(a)  Pharmacological activity residing in a single enantiomer 
The ideal situation is to have the drug pharmacological activity residing in a single 
enantiomer while its antipode is invariably inactive.  This is a rare condition seen with the 
anti-hypertensive drug, α-methyldopa where only the (S)- enantiomer is the pharmacological 
active entity (Gillespie et al., 1962). 
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1.6.2(b) Pharmacological activity residing in both enantiomers 
Drugs like promethazine (Powell et al., 1988) and flecainide (Kroemer et al., 1989) display 
similar pharmacological and toxicological properties in both enantiomers.  Thus treatment 
with either the racemate or single enantiomer does not offer any advantages. 
 
1.6.2(c)  Pharmacological activities of the enantiomers are qualitatively different 
Dextromethorphan and its enantiomer levomethorphan are chiral drugs that exhibit different 
pharmacological activities.  Dextromethorphan does not wield analgesic, sedative, and 
opiod-like effects but levomethorphan exerts potent opiod-like activity (Drayer, 1986). 
 
1.6.2(d) Different potency for pharmacologically similar enantiomers 
Most chiral drugs fall within this category like warfarin and verapamil.  The more potent 
enantiomer is (S)-warfarin.  It is 2-5 times more potent in its anti-coagulant effect than (R)-
warfarin (O’Reilly et al., 1974).  (S)-Verapamil is comparatively eight times more active in 
lowering cardiac activity (Echizen et al., 1985). 
 
1.6.2(e)  Equally active enantiomers with toxicity in one enantiomer 
Ketamine, an anaesthetic with analgesic properties, does not cause circulatory or respiratory 
depression but elicit addiction, hallucination, and agitation.  (S)-ketamine is a 3.4 times more 
effective anaesthetic but its (R)- antipode brings on adverse effects like psychic emergence 
reactions and post-operative agitated behaviour (White et al., 1980). 
 
1.6.2(f)  Opposite or contrary pharmacological activities with each enantiomer 
Indacrinone is a loop diuretic that exhibits diuretic activity with the (-)-indacrinone but 
causes uricosuric activity with the (+)- antipode.  The risk factor for hypertensive patients is 
increased and therefore, it is a more useful diuretic if the (+)- enantiomer proportion is 
increased (Tobert et al., 1981). 
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1.6.2(g)  Antagonism of antipode at the same receptor site 
This is evident with picenadol (a phenylpiperidine derivative) that exerts analgesic properties 
with the (+)- enantiomer but is antagonised by the (-)- enantiomer (Powell et al., 1988). 
 
 
1.6.3 Stereoselectivity in pharmacokinetics 
Chiral drugs not only display stereoselectivity in their pharmacology and 
pharmacodynamics, but also in pharmacokinetics.  In view of the possible enhancing and 
contradictory features of drug enantiomers, it is important to study stereoselectivity in 
pharmacokinetics with regards to the ADME process, as well as stereoselective drug-drug 
interactions (Dong et al., 2011). 
 
1.6.3(a)  Stereoselective absorption 
Absorption of drugs occurs either by passive diffusion or aided by active transport across 
cellular membranes.  Passive diffusion is influenced by lipophilicity, molecular size, and the 
pKa values.  The movement of drug molecules is dictated by the concentration across the cell 
membrane, whereby drug molecules move from higher concentration regions to lower 
concentration regions.  This method of absorption is spontaneous and not stereoselective.  
Active transportation requires energy to transport drug molecules against concentration 
gradient across a biological membrane and thus introduces stereoselectivity in absorption.  
Good synergy between the drug enantiomer and the active transporter improves absorption 
(Dong et al., 2011).  For example L-dopa reacts better with the naturally occurring intestinal 
L-amino acid transporter and thus increases the rate of absorption (Wade et al., 1973). 
 
1.6.3(b) Stereoselective distribution 
Chiral drugs are usually distributed differently from each other because of stereoselectivity 
binding of these drugs to the naturally occurring receptors that are chiral.  Distribution of 
chiral drugs from the plasma to cellular compartment is dependent upon the stereoselective 
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binding to receptors and protein transporters (Dong et al., 2011).  In addition, the binding 
capacity of the drug to plasma and tissue proteins dictates the pharmacodynamics and 
pharmacokinetics.  It is widely accepted that the free or unbound drug is responsible for the 
pharmacological activity and subject to clearance.  Highly protein bound drugs may exhibit 
significant pharmacological effects although there is minor drug-receptor interaction.  
Conversely, low protein binding drugs have increased availability for receptor binding 
resulting in strong pharmacodynamics and pharmacokinetics properties.  Competition for 
plasma protein binding sites gives rise to enantioselective drug interactions.  α1-Acid 
glycoprotein has only one binding site that preferentially recognises basic drugs.  For 
instance, propranolol binding towards α1-acid glycoprotein is predominantly with the (S)- 
enantiomer but its (R)- enantiomer shows remarkable binding capacity with human serum 
albumin (Hutt et al., 1989).  Therefore, the extensive (R)-propranolol binding to human 
serum albumin makes binding of (S)-propranolol of greater significance. 
 
1.6.3(c)  Stereoselective metabolism 
Stereoselectivity happens in both phase I and II metabolism to yield different products, at 
varying rates to form unique enantiomeric metabolites.  Enantioselective metabolism 
involving various stereochemical transformations are summarized in Table 1.5.  
Table 1.5: Summary of various stereochemical transformations involved in stereoselective 
metabolism and examples of each transformation.  * marks the chiral centre of the 
molecules. 
 
Stereochemical 
transformation Examples 
i) Achiral to chiral 
transformation 
An achiral molecule that undergoes metabolic transformation to 
produce a chiral molecule.  E.g. diphenylhydantoin (phenytoin) to 
(S)-4-hydroxydiphenylhydantoin (Poupaert et al., 1975). 
NH
N
H O
O
NH
N
H O
O
OH
*
Diphenylhydantoin (S)-4-hydroxydiphenylhydantoin
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Table 1.5: Continued. 
 
Stereochemical 
transformation Examples 
ii) Chiral to achiral 
transformation 
A rare metabolism transformation at the chiral centre rendering the 
molecule achiral.  E.g. amphetamine to phenylacetone (Wright et 
al., 1977). 
CH3
NH2
CH3
O
*
Amphetamine Phenylacetone
 
iii) Chiral to chiral 
transformation 
Metabolism transformation that retains the chirality of the 
molecule.  E.g. (S)-nirvanol to (S)-4-hydroxynirvanol (Küpfer et 
al., 1984). 
NH
NH
O
O
CH3
NH
NH
O
O
CH3
OH
* *
(S)-nirvanol (S)-4-hydroxynirvanol
 
iv) Chiral to 
diastereomer 
transformation 
Introduction of a new chiral centre to produce varying degrees of 
diastereomerism.  E.g. (R)-pentobarbitone to (1’R,3’S)- and 
(1’R,3’R)- diastereomers and (S)- enantiomer gives rise to 
(1’S,3’R)- and (1’S,3’S)-diastereomers (Palmer et al., 1970). 
N
H
N
H CH3
CH3
CH3
O
O
O
*
1' 3'
Pentobarbitone
N
H
N
H CH3
CH3
CH3
O
O
O
OH
1'
*
*
3'
5-ethyl-5-(pentan-2-yl)pyrimidine
-2,4,6(1H,3H,5H)-trione
5-ethyl-5-(4-hydroxypentan-2-yl)pyrimidine-
2,4,6(1H,3H,5H)-trione
 
v) Chiral inversion Metabolism transformation of a chiral molecule to be converted to 
its antipode.  E.g. (R)-ibuprofen to (2’S,2R)- and ((2’R,2R)-
carboxyibuprofen, and (S)-ibuprofen gives rise to (2’R,2S)- 
(2’S,2S)-carboxyibuprofen (Hutt and Caldwell, 1983). 
CH3
OH
O
CH3
CH3
*
Ibuprofen
CH3
OH
O
CH3
OH
O
*
Carboxyibuprofen
*
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1.6.3(d) Stereoselective excretion 
Glomerular filtration and passive re-uptake in renal excretion are non-stereoselective.  
However, stereoselective binding of drugs to plasma protein influences the process of 
glomerular filtration and passive re-absorption.  Stereoselective renal tubular re-absorption is 
believed to be responsible for the stereoselective excretion of (S)-terbutaline (Borgstorm et 
al., 1989).  Differences in stereoselective renal excretion are relatively small in comparison 
with the non-renal clearance processes. 
 
Stereoselectivity in renal excretion is directly linked to the active tubular excretion where 
drug-receptor interaction and protein binding is prevalent.  Enantiomer administration 
profiles are usually different from the racemate administration.  It is noteworthy that drugs 
and their metabolites have multiple elimination sites and sometimes may not reflect the 
stereoselective secretion process itself.  Thus, an estimation of pharmacokinetic parameters 
and concentration-effect relationships of total drug concentrations may be of limited value 
and potentially misleading (Ariens, 1984). 
 
 
1.6.4 Stereoselective pharmacokinetics of salbutamol 
Salbutamol exerts its desirable bronchodilating property in (R)-salbutamol (eutomer) 
(Brittain et al., 1973) whereas (S)-salbutamol (distomer) causes bronchial contraction and 
hyperresponsiveness towards allergens (Templeton et al., 1998).  Both enantiomers have 
high selectivity for β-adrenoceptors in the bronchial smooth muscle cells compared with 
cardiac muscle cells.   
 
Commercial preparations of salbutamol are introduced via inhalation, oral, and intravenous 
routes (Ward et al., 2000).  In the course of inhalation, salbutamol is usually deposited in 
small portions in the lungs for immediate activity onset and the balance swallowed (Newman 
